老虎證券
Invest
Pricing
Rewards
Support
About
Quotes
TigerAI
登入
立即註冊
Toggle
港股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
生物醫藥B類股
482.357
-14.363
-2.89%
手動刷新
漲家數：
12
跌家數：
18
平家數：
3
市盈率：
- -
高：
497.296
開：
496.590
低：
481.390
收：
496.720
成交量：
7,829.28萬
成交額：
21.60億
市值：
3,067.82億
流通市值：
2,726.46億
資料載入中...
總覽
新聞資訊
歐康維視生物-B：OT-301（NCX 470，比馬前列素格倫諾）在華上市申請獲國家藥監局受理
投资观察
·
09/11
歐康維視生物-B(01477)：OT-301新藥上市註冊申請獲國家藥品監督管理局受理
智通财经
·
09/11
第七批國家組織醫用耗材集中採購開標；諾華大股東呼籲改組董事會｜醫藥早參
每日经济新闻
·
09/11
勁方醫藥-B(02595.HK)9月10日斥資206.3萬港元回購8萬股
智通财经
·
09/11
啓明醫療(02500)發新股及換股債集資5億人民幣
阿斯达克财经
·
09/10
同源康醫藥-B(02410.HK)獲董事長吳豫生增持63.5萬股H股 涉資約209萬港元
中金财经
·
09/10
啓明醫療-B(02500.HK)擬向杭州盈智勤三號股權投資合夥企業發行新股及可轉換債券 募資不超過5億元
智通财经
·
09/10
德琪醫藥-B(06996.HK)授出1152萬份受限制股份單位
智通财经
·
09/10
2026年國家醫保目錄談判收官：「三除外」落地，醫保商保雙軌並行，雙目錄如何重構創新藥支付邏輯
华夏时报网
·
09/10
恒瑞醫藥(01276.HK)自主研發的 1 類創新藥海曲泊帕乙醇胺片獲批新增兩項適應症
智通财经
·
09/10
信立泰重啓H股IPO，創新藥收入站上半壁江山，仍存單品依賴隱憂
蓝鲸财经
·
09/10
ETF日報(09.10)丨臨床風險事件擾動等多因素疊加，創新藥板塊回落 銀行股温和普漲
智通财经
·
09/10
再鼎醫藥(09688)出現大手買入26.84萬股，成交價$18.7，涉資501.908萬
阿斯达克财经
·
09/10
5年13億房租，卡住了「微創系」中報！淄博富豪常兆華再遇難題，高瓴對賭大限將至
时代财经
·
09/10
創勝集團醫藥－Ｂ(06628)股價大幅下跌15.306%，現價港幣$0.83
阿斯达克财经
·
09/10
永泰生物－Ｂ(06978)股價顯著波動12.821%，現價港幣$0.37
阿斯达克财经
·
09/10
歐康維視生物－Ｂ(01477)股價上升6.244%，現價港幣$5.7
阿斯达克财经
·
09/10
京東健康(06618.HK)發布「AI+醫療器械」戰略升級新成果 接入AI產品數量較今年618翻番
智通财经
·
09/10
透景生命(300642.SZ)控股子公司申報醫療器械註冊獲得受理
智通财经
·
09/10
港股異動 | 創新藥概念股繼續走低 國談收官進入結果等待期 海外臨床失敗擾動短期風偏
智通财经
·
09/10
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BK1574/news?page=8"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":482.35672,"timestamp":1789546124622,"preClose":496.71994,"halted":0,"volume":78292841,"delay":0,"changeRate":-0.028916,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":-14.36322,"latestTime":"09-16 16:00:00","open":496.59045,"high":497.2955,"low":481.3899,"amount":2159910416.1,"amplitude":0.032021,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789608600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789522200000,1789531200000],[1789534800000,1789545600000]],"pbRate":3.69899,"peRate":164.598608,"turnoverRate":0.002939,"increases":11,"decrements":18,"flats":3,"marketCap":306781682880,"floatMarketCap":272645614616},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":497.2955,"amplitude":0.032021,"preClose":496.71994,"low":481.3899,"pbRate":"3.69899","latestPrice":482.35672,"volume":78292841,"delay":0,"open":496.59045,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":512.388,"twentyDayClose":492.831,"sixtyDayClose":437.952,"secType":"PLATE","market":"HK","turnoverRate":0.002939,"peRate":164.598608,"marketCap":306781682880,"floatMarketCap":272645614616,"timestamp":1789546124622,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":12,"down":18,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1104990066","title":"歐康維視生物-B：OT-301（NCX 470，比馬前列素格倫諾）在華上市申請獲國家藥監局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1104990066","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104990066?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:13","pubTimestamp":1789081985,"startTime":"0","endTime":"0","summary":"欧康维视生物-B（1477.HK）于9月11日宣布，其核心在研产品OT-301（NCX 470，比马前列素格伦诺）已获中国国家药品监督管理局（NMPA）的新药上市申请（NDA）受理。\n这一进展标志着该创新眼科药物向正式获批上市迈出关键一步。OT-301作为一款新型眼科治疗制剂，其上市申请获得受理，预示着公司有望在中国这一庞大市场中迎来新的增长契机。\n欧康维视生物表示，将继续积极推进OT-301的审评审批进程，力争早日将这一创新疗法带给中国患者。市场分析人士认为，此次NDA获受理对欧康维视生物而言，无疑是一个重要的里程碑事件，有望进一步巩固其在眼科细分领域的竞争优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666197555","title":"歐康維視生物-B(01477)：OT-301新藥上市註冊申請獲國家藥品監督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666197555","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666197555?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:09","pubTimestamp":1789081743,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布公告，OT-301作为降低开角型青光眼或高眼压症患者的眼内压疗法的新药上市注册申请已获中华人民共和国(中国)国家药品监督管理局药品审评中心受理，并获Mont Blanc试验及Denali试验的数据支持。其为一种由Nicox发明的新化学实体，旨在释放贝美前列素及一氧化氮，用于降低开角型青光眼及高眼压症患者的IOP。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1574","BK1191","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666519701","title":"第七批國家組織醫用耗材集中採購開標；諾華大股東呼籲改組董事會｜醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2666519701","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666519701?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:01","pubTimestamp":1789081313,"startTime":"0","endTime":"0","summary":"丨2026年9月11日星期五丨NO.1爱康医疗宣布提高股东股息分派占归母净利比例9月10日，爱康医疗基于对集团未来业绩及长期发展前景的信心，宣布股东股息分派及回报计划，截至2026年12月31日止财政年度，年度股息派付比例提高至不低于归母净利润的55%；截至2027年12月31日及2028年12月31日止财政年度各年，派息比例提升至不低于归母净利润的60%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609113871018788.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609113871018788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NVS","IE0002141913.USD","IE0009355771.USD","BK1161","BK1574","159938","LU0211331839.USD","BK4007","LU0320765489.SGD","BK4578","IE00B4R5TH58.HKD","PPH","09939","IE00B2B36J28.USD","LU0208291251.USD","BK4585","IE00BJJMRZ35.SGD","BK1515","IE00BFTCPJ56.SGD","MEDX","IE00BJT1NW94.SGD","BK4532","LU0070302665.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666251945","title":"勁方醫藥-B(02595.HK)9月10日斥資206.3萬港元回購8萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666251945","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666251945?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 06:59","pubTimestamp":1789081141,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","BK1515","02595","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666590952","title":"啓明醫療(02500)發新股及換股債集資5億人民幣","url":"https://stock-news.laohu8.com/highlight/detail?id=2666590952","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666590952?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 22:49","pubTimestamp":1789051740,"startTime":"0","endTime":"0","summary":"<汇港通讯> 启明医疗(02500)宣布，建议发行新股及可转换债券，集资5亿元人民币。配售股份约1.845亿股。占扩大后股本约29.5%，配售价每股1.078港元，较9月10日收市价每股1.17港元折让约7.9%，代价1.719亿元人民币。可转换债券本金额3.797亿港元，初步转换价每股1.1858港元，较9月10日收市价溢价约1.4%。认购所得款项总额约5亿元人民币，净额约4.765亿元人民币，其中约25.2%用于支付研发、临床及监管费用；约43.3%补充一般企业营运资金需求；约31.5%用作偿还未偿还贷款。 (WH)新闻来源 (不包括新闻图片): 汇港资讯","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20201222151859290_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20201222151859290_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/IC4989087/latest-news/INFOCAST","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/IC4989087/latest-news/INFOCAST","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["CYB","02500","MUCmain","UCmain","BK1583","BK1574","BK1100","CNHmain","MCNHmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666594669","title":"同源康醫藥-B(02410.HK)獲董事長吳豫生增持63.5萬股H股 涉資約209萬港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666594669","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666594669?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 22:47","pubTimestamp":1789051624,"startTime":"0","endTime":"0","summary":"格隆汇9月10日丨同源康医药-B(02410.HK)公告，公司董事长、执行董事兼总裁吴豫生已告知公司，于2026年9月8日至2026年9月10日期间，其于公开市场购入63.5万股公司H股(占公司已发行股本总额约0.17%)，总代价约为209万港元。吴豫生已告知公司，其未来可能继续根据市场情况购买公司股份。目前预计其将在此基础上进一步购买股份的总金额不超过300万港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260910/32366677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1515","09939","159938","BK1161","02410","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666967845","title":"啓明醫療-B(02500.HK)擬向杭州盈智勤三號股權投資合夥企業發行新股及可轉換債券 募資不超過5億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666967845","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666967845?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 21:20","pubTimestamp":1789046454,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","02500","BK1574","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666938635","title":"德琪醫藥-B(06996.HK)授出1152萬份受限制股份單位","url":"https://stock-news.laohu8.com/highlight/detail?id=2666938635","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666938635?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 20:04","pubTimestamp":1789041856,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1574","BK1191","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666560028","title":"2026年國家醫保目錄談判收官：「三除外」落地，醫保商保雙軌並行，雙目錄如何重構創新藥支付邏輯","url":"https://stock-news.laohu8.com/highlight/detail?id=2666560028","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666560028?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 19:12","pubTimestamp":1789038763,"startTime":"0","endTime":"0","summary":"9月9日正午，北京西黄城根北街2号全国人大会议中心。最后一家参与商保创新药目录价格协商的企业代表走出大门，历时五天的2026年国家医保目录现场谈判竞价与商保创新药目录价格协商正式收官。新版国家基本医保药品目录与商保创新药目录预计今年11月公布，2027年1月1日起统一执行。五天时间里，124个目录外药品先后完成基本医保谈判竞价，12个创新药冲击商保创新药目录价格协商。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609103870706515.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609103870706515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","MEDX","159992","06978","IBBQ","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666856717","title":"恒瑞醫藥(01276.HK)自主研發的 1 類創新藥海曲泊帕乙醇胺片獲批新增兩項適應症","url":"https://stock-news.laohu8.com/highlight/detail?id=2666856717","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666856717?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 18:48","pubTimestamp":1789037303,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06978","LU0359202008.SGD","LU1023057109.AUD","BK1161","LU0359201885.HKD","BK1574","01276","LU2543165471.USD","BK1191","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666648561","title":"信立泰重啓H股IPO，創新藥收入站上半壁江山，仍存單品依賴隱憂","url":"https://stock-news.laohu8.com/highlight/detail?id=2666648561","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666648561?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 17:29","pubTimestamp":1789032552,"startTime":"0","endTime":"0","summary":"业务层面，信立泰转型取得阶段性成果的同时，核心产品收入集中的风险始终悬而未决。作为转型最重要的产品，信立坦2024 年销售额约 15 亿元，是公司创新药板块最主要的收入来源，公司创新药板块收入高度依赖这一款降压药物。虽然后续信超妥、复立坦、复立安等多款创新产品陆续获批、纳入医保，形成产品梯队，但是这些新产品体量尚小，短期内难以替代信立坦的收入贡献，公司仍然处于单品依赖阶段。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789029785904368871","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0239","KCE","BK0187","FRHC","LNGR","IPOS","159992","002294","REDS","BK1161","BK4127","BK1574","06978","BK0196","BK0188","IBBQ","MEDX","BK0183","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666693435","title":"ETF日報(09.10)丨臨床風險事件擾動等多因素疊加，創新藥板塊回落 銀行股温和普漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2666693435","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666693435?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 16:43","pubTimestamp":1789029788,"startTime":"0","endTime":"0","summary":"临床风险事件扰动等多因素叠加，创新药板块集体回落；定增政策红利释放、中报验证盈利韧性，银行板块温和普涨。行业表现临床风险事件扰动、海外利率预期反复与资金风格轮动三重因素叠加，创新药板块集体回落。截至收盘，恒生创新药ETF华泰柏瑞跌2.93%，报1.356元；港股通创新药ETF工银跌2.67%，报1.132元；港股创新药ETF广发跌2.65%，报1.251元。截至收盘，银行AH优选ETF招商涨1.65%，报1.603元；银行ETF汇添富涨1.56%，报1.5元；银行ETF华夏涨1.39%，报1.829元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ABEQ","ROPE","VALQ","BK1161","IBBQ","PRF","EQRR","MEDX","DFLV","TALV","VLUE","BKDV","PY","SPVM","VTV","BK4588","CGVV","BK4550","BK4585","LNGR","FDN","BK1574","159992","VUSV","SWP","06978","VMAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666653565","title":"再鼎醫藥(09688)出現大手買入26.84萬股，成交價$18.7，涉資501.908萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2666653565","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666653565?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 15:34","pubTimestamp":1789025640,"startTime":"0","endTime":"0","summary":"[大手成交]再鼎医药(09688)在下午03:34出现大手买入，成交量为26.84万，成交价为港币$18.7，涉资501.908万。至目前为止，股价跌6.6%，今日最高价为$19.99，而最低价为$18.63，总成交量为774.13万股，总成交金额港币$1.475亿。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609105363/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609105363/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","09688","BK1588","BK1161","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666653685","title":"5年13億房租，卡住了「微創系」中報！淄博富豪常兆華再遇難題，高瓴對賭大限將至","url":"https://stock-news.laohu8.com/highlight/detail?id=2666653685","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666653685?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 15:27","pubTimestamp":1789025220,"startTime":"0","endTime":"0","summary":"一纸租房合同，直接引发微创医疗（00853.HK）、微创机器人（02252.HK）、心通医疗（02160.HK）、微创脑科学（02172.HK）四家港股上市公司集体停牌，中报延期。上海张江科学城张东路沿线，两座园区比邻而居，北侧为位于张东路1601号的微创集团总部，与之紧邻的南侧，便是引发本次房租争议的位于张东路1661号的物业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609103870530297.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609103870530297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00853","BK1258","03913","BK1583","BK1585","BK1100","BK1589","BK1617","688351","02160","BK1542","BK0251","02172","BK1229","BK1574","688277","688016","02252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666550210","title":"創勝集團醫藥－Ｂ(06628)股價大幅下跌15.306%，現價港幣$0.83","url":"https://stock-news.laohu8.com/highlight/detail?id=2666550210","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666550210?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 14:10","pubTimestamp":1789020600,"startTime":"0","endTime":"0","summary":"[下跌股]创胜集团医药－Ｂ(06628) 股价在下午02:10比前收市价大幅下跌15.306%，现股价为港币$0.83。至目前为止，今日最高价为$0.98，而最低价为$0.83。总成交量为125.3万股，总成交金额为港币$113.524万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609102348/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609102348/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","159938","09939","06628","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666550618","title":"永泰生物－Ｂ(06978)股價顯著波動12.821%，現價港幣$0.37","url":"https://stock-news.laohu8.com/highlight/detail?id=2666550618","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666550618?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 13:54","pubTimestamp":1789019640,"startTime":"0","endTime":"0","summary":"[异动股]永泰生物－Ｂ(06978) 股价在下午01:54出现显著波动12.821%，现股价为港币$0.37，比前收市价下跌5.128%5.128%。至目前为止，今日最高价为$0.415，而最低价为$0.365。总成交量为11.9万股，总成交金额为港币$4.696万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131623256_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131623256_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAC26091052/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAC26091052/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666557473","title":"歐康維視生物－Ｂ(01477)股價上升6.244%，現價港幣$5.7","url":"https://stock-news.laohu8.com/highlight/detail?id=2666557473","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666557473?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 13:34","pubTimestamp":1789018440,"startTime":"0","endTime":"0","summary":"[上升股]欧康维视生物－Ｂ(01477) 股价在下午01:34比前收市价上升6.244%，现股价为港币$5.7。至目前为止，今日最高价为$5.7，而最低价为$5.335。总成交量为35.634万股，总成交金额为港币$196.122万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609101507/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609101507/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666557852","title":"京東健康(06618.HK)發布「AI+醫療器械」戰略升級新成果 接入AI產品數量較今年618翻番","url":"https://stock-news.laohu8.com/highlight/detail?id=2666557852","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666557852?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 13:00","pubTimestamp":1789016408,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1142","BK1574","BK1615","86618","SGXZ62798434.SGD","SGXZ86797644.SGD","BK1571","BK1591","LU0051755006.USD","09996","06618","BK1589","BK1515","LU0456827905.SGD","BK1247","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666755282","title":"透景生命(300642.SZ)控股子公司申報醫療器械註冊獲得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666755282","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666755282?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 11:50","pubTimestamp":1789012238,"startTime":"0","endTime":"0","summary":"智通财经APP讯，透景生命(300642.SZ)发布公告，公司控股子公司上海脉示生物技术有限公司申报的医疗器械注册申请于近日获得了上海市药品监督管理局的受理，产品名称：四项抗癫痫药物浓度测定试剂盒(液相色谱串联质谱法)。该产品用于检测人体血清样本中的丙戊酸、奥卡西平代谢物(10,11-二氢-10-羟基卡马西平)、托吡酯、左乙拉西坦浓度。临床上用于丙戊酸、奥卡西平代谢物(10,11-二氢-10-羟基卡马西平)、托吡酯、左乙拉西坦血药浓度的监测。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09996","BK0046","BK1583","MEDX","BK1100","BK0239","LNGR","AGNG","BK0042","HART","RSPH","PTH","300642","IEIH","BK1574","LGHT","MDEV","GDOC","159883"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666755104","title":"港股異動 | 創新藥概念股繼續走低 國談收官進入結果等待期 海外臨床失敗擾動短期風偏","url":"https://stock-news.laohu8.com/highlight/detail?id=2666755104","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666755104?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 10:43","pubTimestamp":1789008234,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06978","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":8,"totalSize":329,"code":"91000000","status":"200"}]}}